Condition or Therapy: Relapsed or refractory neuroblastoma
Category: Cancer and Blood Disorders

What is the goal of this study?

Seattle Children’s is currently enrolling patients in a phase 1 clinical trial that is testing T-cell therapy in children and young adults with recurrent or refractory neuroblastoma who are not likely to survive with current treatments. This trial is known as Engineered Neuroblastoma Cellular Immunotherapy (ENCIT-01). Through this trial, researchers are working to answer these questions:

  • Is T-cell therapy safe to give to children and young adults with recurrent or refractory neuroblastoma? 
  • What is the largest dose that children and young adults can stand (the maximum tolerated dose)? 
  • Does T-cell therapy work against neuroblastoma?

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are 1 to 18 years old
  • Have high-risk neuroblastoma and have responded poorly to standard treatments (chemotherapy, radiation therapy or both) 
  • Have had their neuroblastoma come back (a recurrence) after treatment 

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What happens in the study?

You can read about the ENCIT-01 study protocol on clinicaltrials.gov.

Who can I contact for information or to enroll?

For more information, please call 206-987-2106 or send us an email.


Study Location(s): Seattle Children's Hospital main campus
Principal Investigator: Dr. Julie Park